BackgroundNewer molecular testing platforms are now available for deployment at lower-level community health centers. There are limited data on facility- and health worker-level factors that would promote successful adoption of such platforms for rapid tuberculosis (TB) testing and treatment initiation. Our study aimed to assess readiness to implement onsite molecular testing at community health centers in Uganda, a high TB burden country in sub-Saharan Africa.MethodsTo understand implementation readiness, we conducted a qualitative assessment guided by the Consolidated Framework for Implementation Research (CFIR) at 6 community health centers in central and eastern Uganda between February and April 2018. We conducted 23 in-depth, semi-stru...
99DOTS is a low-cost digital adherence technology that allows people with tuberculosis (TB) to self-...
Abstract Background Multidrug-resistant tuberculosis (MDR-TB) outcomes are adversely impacted by del...
BACKGROUND: Programmes that introduce rapid molecular tests for tuberculosis and tuberculosis drug r...
BackgroundNewer molecular testing platforms are now available for deployment at lower-level communit...
Nucleic acid amplification tests such as Xpert MTB/RIF (Xpert) have the potential to revolutionize t...
BackgroundDelays in diagnosis and treatment of tuberculosis (TB) remain common in high-burden countr...
Background: Early access to diagnosis is crucial for effective management of any disease including t...
Background Early access to diagnosis is crucial for effective management of any disease including tu...
The World Health Organization's 2035 vision is to reduce tuberculosis (TB) associated mortality by 9...
IntroductionTuberculosis (TB) remains a major cause of morbidity and mortality, especially in sub-Sa...
BACKGROUND: Effective strategies are needed to facilitate the prompt diagnosis and treatment of tube...
BackgroundThe WHO END TB strategy targets to place at least 90% of all patients diagnosed with ...
Introduction: Current evidence indicates that the impact of GeneXpert for diagnosing TB in low- and...
Background: Efforts to reduce Tuberculosis (TB) incidence and improve patient outcomes should result...
BACKGROUND: Programmes that introduce rapid molecular tests for tuberculosis and tuberculosis drug r...
99DOTS is a low-cost digital adherence technology that allows people with tuberculosis (TB) to self-...
Abstract Background Multidrug-resistant tuberculosis (MDR-TB) outcomes are adversely impacted by del...
BACKGROUND: Programmes that introduce rapid molecular tests for tuberculosis and tuberculosis drug r...
BackgroundNewer molecular testing platforms are now available for deployment at lower-level communit...
Nucleic acid amplification tests such as Xpert MTB/RIF (Xpert) have the potential to revolutionize t...
BackgroundDelays in diagnosis and treatment of tuberculosis (TB) remain common in high-burden countr...
Background: Early access to diagnosis is crucial for effective management of any disease including t...
Background Early access to diagnosis is crucial for effective management of any disease including tu...
The World Health Organization's 2035 vision is to reduce tuberculosis (TB) associated mortality by 9...
IntroductionTuberculosis (TB) remains a major cause of morbidity and mortality, especially in sub-Sa...
BACKGROUND: Effective strategies are needed to facilitate the prompt diagnosis and treatment of tube...
BackgroundThe WHO END TB strategy targets to place at least 90% of all patients diagnosed with ...
Introduction: Current evidence indicates that the impact of GeneXpert for diagnosing TB in low- and...
Background: Efforts to reduce Tuberculosis (TB) incidence and improve patient outcomes should result...
BACKGROUND: Programmes that introduce rapid molecular tests for tuberculosis and tuberculosis drug r...
99DOTS is a low-cost digital adherence technology that allows people with tuberculosis (TB) to self-...
Abstract Background Multidrug-resistant tuberculosis (MDR-TB) outcomes are adversely impacted by del...
BACKGROUND: Programmes that introduce rapid molecular tests for tuberculosis and tuberculosis drug r...